Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.Cancer Immunology, Immunotherapy : CII|November 6, 2013
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trialRyan D Guest, Natalia Kirillova, Sam Mowbray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)Cristina Suárez, James M G Larkin, Poulam Patel, et al.Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.The Lancet. Oncology|July 2, 2019
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Carla M L van Herpen, Cristina Saura, et al.The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.Cancer Medicine|March 19, 2024
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumorsDejan Juric, Minal Barve, Ulka Vaishampayan, et al.Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.Pageof 5